Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence
Posted: 25 November 2013 | | No comments yet
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named “Clinical Advance of the Year” by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical industry publication.
Dupilumab is a fully-human monoclonal antibody that is in clinical development for treatment of asthma, atopic dermatitis, and nasal polyposis. Dupilumab is being developed by Regeneron and Sanofi.
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories and Chief Scientific Officer, said, “We appreciate the recognition by Scrip that dupilumab is one of the most exciting emerging clinical candidates in the industry. We also feel that this award is additional validation of the overall depth and productivity of our R&D team and the powerful VelociSuite® technologies they employ.”
“On behalf of all of the men and women within our organizations working diligently to develop this investigation treatment, we are truly honored by this award,” said Elias Zerhouni, MD, President Global R&D, Sanofi. “The ultimate recognition for their innovative research, at the end of the day, is when we are able to deliver improved solutions to patients.”
Award winners were selected by a 15-member panel of leading pharmaceutical industry executives, consultants, and researchers. More information about the panel is available here: http://www.scripintelligence.com/awards/judges/. In 2012, Scrip honored Regeneron as its Biotech Company of the Year.
